Literature DB >> 22306

Sjögren-type syndrome after allogeneic bone-marrow transplantation.

A A Gratwohl, A A Gratwhol, H M Moutsopoulos, T M Chused, M Akizuki, R O Wolf, J B Sweet, A B Deisseroth.   

Abstract

Four patients, treated for hematologic disorders with bone-marrow transplants from HLA-identical siblings, spontaneously complained of dry eyes 8 to 12 months after transplantation. Four allograft recipients and two recipients of autologous bone-marrow transplants were evaluated for xerophthalmia and xerostomia. Three allogeneic marrow recipients had evidence of keratoconjunctivitis sicca, and two had decreased parotid gland function. All four allograft recipients had minor salivary gland histopathology identical to that of Sjögren's syndrome. The severity of symptoms and histologic lesions corresponded with the severity of chronic graft-versus-host disease. In addition, one patient developed sclerodermatous skin changes, another had discoid lupus erythematosus, and two patients had laboratory evidence of cholestasis. None of the patients had autoantibodies but all had hypergammaglobulinemia. In contrast, none of the recipients of autologous bone marrow had clinical, laboratory, or histologic findings resembling Sjögren's syndrome.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 22306     DOI: 10.7326/0003-4819-87-6-703

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  26 in total

1.  Non-host cells in the pathogenesis of autoimmune disease: a new paradigm?

Authors:  J L Nelson
Journal:  Ann Rheum Dis       Date:  1999-09       Impact factor: 19.103

2.  Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Authors:  M Y Detrait; S Morisset; R Peffault de Latour; I Yakoub-Agha; R Crocchiolo; R Tabrizi; J-O Bay; P Chevalier; F Barraco; N Raus; S Vigouroux; L Magro; M Mohty; N Milpied; D Blaise; G Socié; M Michallet
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

Review 3.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 4.  Oral graft-versus-host disease.

Authors:  M M Imanguli; I Alevizos; R Brown; S Z Pavletic; J C Atkinson
Journal:  Oral Dis       Date:  2008-07       Impact factor: 3.511

5.  Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation.

Authors:  A Salhotra; N Tsai; S H Thomas; T Paris; P Parker; S J Forman; R Nakamura
Journal:  Bone Marrow Transplant       Date:  2014-09-29       Impact factor: 5.483

Review 6.  New perspectives on the use of mTOR inhibitors in allogeneic haematopoietic stem cell transplantation and graft-versus-host disease.

Authors:  Mathias Lutz; Stephan Mielke
Journal:  Br J Clin Pharmacol       Date:  2016-06-22       Impact factor: 4.335

Review 7.  Bone marrow transplantation. Part I--Allogeneic.

Authors:  N J Chao; K G Blume
Journal:  West J Med       Date:  1989-12

Review 8.  Duct-associated lymphoid tissue (DALT) of minor salivary glands and mucosal immunity.

Authors:  P N Nair; H E Schroeder
Journal:  Immunology       Date:  1986-02       Impact factor: 7.397

9.  Lymphocytic infiltration and HLA-DR expression of salivary glands in bone marrow transplant recipients: a prospective study.

Authors:  G Lindahl; B Lönnquist; E Hedfors
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

Review 10.  Lessons from diseases mimicking Sjögren's syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Josep Font
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.